Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Scott M. Frisch Insider Profile
4 Followers
Scott M. Frisch, Director at Carmell Therapeutics, holds 7.60K shares in Carmell Therapeutics (Ticker: CTCX). Most recently, Scott M. Frisch Bought $1,009 shares of Carmell Therapeutics on Sep 10, 2024 for an estimated value of 514.59.
Profitable Transactions
0 out of 6 Profitable Transactions
Average Return
-76.20%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Scott M. Frisch's holdings
Insider Roles
Director
Roles that Scott M. Frisch holds in companies
Most Profitable Insider Trade
The most profitable trade made by Scott M. Frisch
Scott M. Frisch's Trading History
List of latest transactions for each holding click on a transaction to see Scott M. Frisch's performance on stock
You May Also Like
Scott M. Frisch insider profile FAQ
What is the percentage of profitable transactions made by Scott M. Frisch?
The percentage of profitable transactions made by Scott M. Frisch is 0%.
What is the average return per transaction made by Scott M. Frisch?
The average return per transaction made by Scott M. Frisch is -76.20%.
What stocks does Scott M. Frisch hold?
Scott M. Frisch holds: CTCX stocks.
What was Scott M. Frisch’s latest transaction?
Scott M. Frisch latest transaction was an Informative Buy of $514.59.
What was Scott M. Frisch's most profitable transaction?
Scott M. Frisch’s most profitable transaction was an Informative Buy of CTCX stock on September 10, 2024. The return on the trade was -53.10%.
What is Scott M. Frisch's role in Carmell Therapeutics?
Scott M. Frisch's role in Carmell Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.